Guggenheim analyst Vamil Divan maintained a Buy rating on Pfizer (PFE – Research Report) yesterday. The company’s shares closed yesterday at ...

Pfizer (PFE) announced that James List has joined the company as Chief Internal Medicine Officer. List will oversee Pfizer’s Internal Medicine portfolio and will be responsible for advancing the ...

Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. The New York pharma is ending global development and commercialization of ...

March 6 (Reuters) - Pfizer (PFE.N), opens new tab on Thursday named James List as the head of the drugmaker's Internal Medicine portfolio, where he will oversee the development of its closely ...

March 3 (Reuters) - Pfizer (PFE.N), opens new tab CEO Albert Bourla said on Monday the drugmaker might move overseas manufacturing to its existing plants in the United States, if required ...

Pfizer hopes a unique life-extension benefit for its Talzenna can serve to further expand the drug’s already broadest-in-class U.S. label in prostate cancer. Following an FDA approval in 2023 ...

Pfizer generated strong growth last year despite a significant drop in COVID revenue. The company's business is solid, and its growth prospects are encouraging. Investors, however, remain ...

(Reuters) -Pfizer CEO Albert Bourla said on Monday the drugmaker might move overseas manufacturing to its existing plants in the United States, if required, as the Trump administration threatens ...

Pfizer Ltd on Friday said its board approved signing a marketing and supply agreement with Mylan Pharmaceuticals Pvt Ltd for two of its brands -- Ativan and Pacitane. Ativan is used for the treatment ...

A post is doing rounds on social media claiming that vaccine maker Pfizer's COVID vaccines have side effects including few fatal ones. The posts have shared a report with the logo of the US House ...

Pfizer stock has suffered as demand for the company’s top selling coronavirus products declined. The pharma giant has reached an important transition point. Right now, as an investor, you may be ...

Fresh from the $43 billion acquisition of antibody-drug conjugate (ADC) specialist Seagen, Pfizer has laid out plans for its dedicated oncology division in front of investors, aiming to add eight ...